Our findings demonstrate that S-GLSP alleviates Alzheimer’s disease pathology by inhibiting NLRP3 inflammasome activation, promoting a shift in microglial polarization from the M1 to the M2 phenotype, and modulating the release of inflammatory cytokines. Here, NLRP3 is linked to Alzheimer disease.